A patient who heals stops spreading bacteria to their community
En un laboratorio de la Universidad de Buenos Aires, la inmunóloga Luciana Balboa y su equipo trabajan para acortar el tratamiento de la tuberculosis no inventando un fármaco nuevo, sino reactivando las defensas del propio cuerpo. La enfermedad mata a mil argentinos por año y afecta desproporcionadamente a quienes menos recursos tienen para sostener seis meses de medicación diaria; cuando el tratamiento se abandona, las bacterias se vuelven resistentes y el ciclo se agrava. La estrategia propuesta —usar un medicamento para el asma ya aprobado que bloquea los lípidos que debilitan las células inmunes— es tan elegante como urgente, aunque su camino hacia los ensayos clínicos depende de voluntad política y financiamiento que hoy escasean.
- La tuberculosis no es historia pasada: con 16.000 casos y 1.000 muertes anuales en Argentina, la enfermedad sigue siendo una crisis de salud pública activa y en crecimiento.
- El verdadero peligro no es solo el bacilo sino el abandono del tratamiento: pacientes que se sienten mejor a las pocas semanas dejan la medicación, y las bacterias que sobreviven se vuelven resistentes a los antibióticos de primera línea.
- El equipo de Balboa identificó que la bacteria manipula el sistema inmune mediante lípidos que paralizan los macrófagos, y propone bloquear esa trampa con un fármaco antiasmático ya aprobado por la FDA.
- Los resultados en laboratorio son prometedores —los macrófagos tratados eliminan el bacilo con mayor eficacia junto a antibióticos—, pero el salto a ensayos clínicos en humanos exige recursos que el Estado argentino ya no garantiza.
- Balboa sostiene la investigación con subsidios internacionales asegurados por dos años; más allá de ese horizonte, el futuro del proyecto es incierto, exponiendo la fragilidad estructural de la ciencia pública argentina.
En un laboratorio de la UBA, la inmunóloga Luciana Balboa lidera una investigación que no busca crear un nuevo fármaco sino potenciar las defensas del organismo contra la tuberculosis. Su equipo descubrió que el bacilo no solo ataca al sistema inmune: lo manipula. Lípidos específicos debilitan a los macrófagos —las células encargadas de destruir la bacteria— y la propuesta es bloquear esa producción con un medicamento para el asma ya aprobado por la FDA, permitiendo que los antibióticos actúen con mayor eficacia y, potencialmente, en menos tiempo.
La tuberculosis mata a cerca de mil personas por año en Argentina y los casos han trepado a unas 16.000 infecciones anuales. Se transmite por el aire y, aunque afecta principalmente los pulmones, puede dañar el cerebro, los ganglios o la columna. El tratamiento estándar exige tomar cuatro antibióticos distintos durante seis meses, una exigencia que resulta casi imposible de sostener para quienes viven en situación de pobreza o precariedad laboral. Cuando los pacientes abandonan la medicación al sentirse mejor, las bacterias sobrevivientes se adaptan y se vuelven resistentes; los médicos deben entonces recurrir a drogas de segunda línea más tóxicas, más costosas y menos efectivas. Acortar ese tratamiento podría romper ese ciclo.
Los resultados preliminares en cultivos celulares son alentadores: los macrófagos tratados con este enfoque eliminan el bacilo con mayor eficacia al combinarse con antibióticos. Pero la investigación sigue en fase preclínica y el camino hacia ensayos en humanos es largo e incierto.
Lo que hace aún más notable este trabajo son las condiciones en que se sostiene. El gobierno argentino ha recortado drásticamente el financiamiento científico, y Balboa —docente de inmunología en la facultad de medicina— mantiene el laboratorio vivo gracias a subsidios internacionales con vigencia de dos años. "Es inadmisible que no abordemos estos problemas con voluntad política seria", afirmó. La paradoja es elocuente: una universidad pública, con investigadores públicos, trabajando sobre una crisis de salud pública, financiada desde el exterior porque el propio Estado se ha retirado. La tuberculosis en Argentina no es aleatoria; se concentra en los barrios más pobres, entre quienes menos pueden permitirse medio año de tratamiento. Reducir ese plazo, aunque sea por semanas, podría significar la diferencia entre la cura y la resistencia.
In a laboratory at the University of Buenos Aires, researchers are pursuing a strategy that could reshape how tuberculosis is treated in Argentina—not by inventing a new drug, but by waking up the body's own defenses. The work, led by immunologist Luciana Balboa, centers on a simple but powerful insight: the bacteria that causes tuberculosis doesn't just attack the immune system; it manipulates it. Balboa's team identified specific lipids—fatty molecules—that weaken the macrophages, the white blood cells responsible for destroying the tuberculosis bacterium. The solution they're testing is equally elegant: use an asthma medication already approved and in use, one that blocks the production of these lipids, allowing the immune system to work more efficiently alongside antibiotics.
Tuberculosis has never left Argentina. The disease kills roughly a thousand people each year in the country, and cases have climbed steadily in recent years to around sixteen thousand annually. It spreads through the air—a cough, a sneeze, respiratory droplets—and while it typically settles in the lungs, it can damage the brain, lymph nodes, or spine. The disease is not a relic. Globally, nearly eleven million people carry active tuberculosis, and more than a million die from it annually, according to the World Health Organization. Yet in Argentina, as elsewhere, the real crisis isn't the disease itself but what happens when treatment fails.
The standard cure requires six months of four different antibiotics taken daily. That length is the problem. In vulnerable populations—people living in poverty, those with unstable housing, those working precarious jobs—sustaining a half-year regimen is nearly impossible. After a few weeks, patients often feel better and stop taking their pills. When they do, the bacteria left behind don't die; they adapt. They become resistant. Then doctors must switch to second-line drugs that are far more toxic, far more expensive, and far less likely to work. This cascade of treatment failure and drug resistance is one of the most dangerous public health patterns in Argentina today. Balboa explained the stakes plainly: when a patient abandons treatment, they continue spreading the disease to others in their community. A shorter treatment window could break that cycle.
The research doesn't aim to replace antibiotics but to amplify them. By using the asthma drug to enhance immune response, Balboa's team hopes to help the antibiotics kill the bacteria faster, giving patients a reason to stay the course. The work is still in the preclinical phase—laboratory experiments, not yet human trials—but the early results are encouraging. In test-tube studies, macrophages treated with this approach eliminate the tuberculosis bacterium more effectively when paired with antibiotics. The path to clinical trials in humans remains long and uncertain.
What makes this research remarkable is not just the science but the conditions under which it survives. Argentina's government has dramatically cut funding for scientific research and development. Balboa, who teaches immunology at the medical school, earns three hundred thousand pesos monthly—roughly equivalent to a modest salary in many countries—while trying to solve a disease that kills a thousand of her countrymen each year. The laboratory runs on international grants. She has funding secured for two more years. After that, she doesn't know. "It's inadmissible that we don't approach these problems with serious political will," she said, her frustration evident. The irony is sharp: a public university, with public researchers, working on a public health crisis, kept alive by money from abroad because the nation itself has stepped back.
The research sits at the intersection of biology and inequality. Tuberculosis in Argentina is not random. It clusters in poor neighborhoods, in communities with weak healthcare access, among people whose economic precarity makes a six-month treatment regimen a luxury they cannot afford. Shortening that timeline, even by weeks, could mean the difference between cure and abandonment, between health and the spread of resistant strains. Balboa's team is not waiting for perfect conditions or abundant resources. They are working with what they have, in circumstances far from ideal, trying to solve a problem that the state has largely abandoned to them. The next phase—moving from laboratory to human trials—will require not just scientific skill but also the kind of sustained commitment and funding that, in Argentina right now, is increasingly hard to find.
Notable Quotes
If the patient stops taking medication, the bacteria that remain start to multiply and become resistant. This forces doctors to use second-line drugs that are more toxic and costly.— Dr. Luciana Balboa
We're not trying to replace antibiotics, but to help them work faster by strengthening the patient's own immune response.— Dr. Luciana Balboa
The Hearth Conversation Another angle on the story
Why focus on the immune system rather than developing a new antibiotic?
Because the bacteria are already becoming resistant to antibiotics we have. A new drug just delays the problem. But if we make the immune system more efficient, we're working with the patient's own biology—something the bacteria can't easily adapt to.
The source mentions that patients stop taking their pills after a few weeks. Why does that happen?
Mostly because they feel better. The symptoms fade, the fever breaks, and they think they're cured. But the bacteria are still there, dormant. When they stop the medication, those bacteria wake up and multiply. For someone living paycheck to paycheck, working an unstable job, the burden of six months of daily pills is just too much.
What happens when treatment is abandoned?
The bacteria that survive become resistant to the drugs that killed their siblings. Then you need second-line medications that are more toxic, more expensive, and often less effective. It's a trap. And the patient keeps spreading the disease to people around them.
How far along is this research?
Still in the lab. We've shown in test tubes that the approach works—the immune cells kill the bacteria more effectively. But human trials are years away, and that's only if we can secure funding.
Funding is the real bottleneck, isn't it?
Completely. The government has cut science funding dramatically. Dr. Balboa teaches full-time for a modest salary and runs this research on international grants. She has two years of funding left. After that, she doesn't know what happens.
So a disease that kills a thousand Argentines a year is being studied by researchers the state has essentially abandoned?
Yes. And the people most affected—the poor, the vulnerable—are the ones who can't sustain long treatments anyway. It's a crisis within a crisis.